切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2026, Vol. 15 ›› Issue (05) : 823 -830. doi: 10.3877/cma.j.issn.2095-3232.2026.05.020

综述

外泌体在胆管癌诊疗中的价值研究进展
李优伟1,2, 荣冬梅3, 张宗明1,4,†()   
  1. 1　100073　北京，中国通用技术集团肝胆疾病临床医学研究中心（筹）
    2　100144　首都医科大学附属北京康复医院放射科
    3　100039　北京，航天中心医院党委工作处
    4　100073　国家电网公司北京电力医院普通外科
  • 收稿日期:2026-04-05 出版日期:2026-10-10
  • 通信作者: 张宗明
  • 基金资助:
    北京市科技重大专项生物医药与生命科学创新培育研究(Z171100000417056); 国中康健集团科技项目(GZKJ-KJXX-QTHT-20230626，20240429)

Research progress in diagnostic and therapeutic value of exosomes for cholangiocarcinoma

Youwei Li1,2, Dongmei Rong3, Zongming Zhang1,4,†()   

  1. 1 Clinical Research Center for Hepatobiliary Diseases (in preparation), China General Technology Group, Beijing 100073, China
    2 Department of Radiology, Beijing Rehabilitation Hospital Affiliated to Capital Medical University, Beijing 100144, China
    3 Party Committee Office, Aerospace Center Hospital, Beijing 100039, China
    4 Department of General Surgery, Beijing Electric Power Hospital, State Grid Corporation of China, Beijing 100073, China
  • Received:2026-04-05 Published:2026-10-10
  • Corresponding author: Zongming Zhang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李优伟, 荣冬梅, 张宗明. 外泌体在胆管癌诊疗中的价值研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(05): 823-830.

Youwei Li, Dongmei Rong, Zongming Zhang. Research progress in diagnostic and therapeutic value of exosomes for cholangiocarcinoma[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2026, 15(05): 823-830.

胆管癌是一种侵袭性强、预后差的恶性肿瘤，现有诊断标志物灵敏度和特异度较差，亟待探索新方法。外泌体作为携带有蛋白质、脂质、非编码RNA等生物活性分子的囊性小泡，在胆管癌进展中发挥关键作用。其蛋白质如B细胞特异性莫洛尼鼠白血病病毒整合位点1、肝脏激酶B1，脂质如磷脂酰胆碱，非编码RNA如miR-200家族、circ_0000284等，参与肿瘤增殖、侵袭、转移及耐药等过程。胆管癌组织、胆汁及血液中的外泌体成分各具诊断价值，且外泌体可作为药物载体用于靶向治疗。然而，外泌体分离技术标准化、作用机制研究及临床转化等仍面临挑战，未来需进一步突破以实现其诊疗潜力。

关键词: 胆管癌, 外泌体, 肿瘤微环境, 诊断标志物, 治疗靶点

Cholangiocarcinoma is a malignant tumor with strong invasiveness and poor prognosis. The sensitivity and specificity of existing diagnostic markers are relatively low, and novel methods urgently need to be explored. Exosomes, as cystic vesicles carrying bioactive molecules such as proteins, lipids and non-coding RNAs, play a key role in the progression of cholangiocarcinoma. Proteins, such as B-cell specific Moloney murine leukemia virus integration site 1, liver kinase B1, lipids such as phosphatidylcholine, and non-coding RNAs such as miR-200 family and circ_0000284, are involved in the processes of tumor proliferation, invasion, metastasis and drug resistance. Exosomes in cholangiocarcinoma tissues, bile and blood have specific diagnostic values. Moreover, exosomes can be used as drug carriers for targeted therapy.However, the standardization of exosome separation technology, mechanism and clinical translation still face challenges. Efforts should be made for further breakthroughs to achieve diagnostic and therapeutic potentials.

Key words: Cholangiocarcinoma, Extracellular vesicles, Tumor microenvironment, Diagnostic marker, Therapeutic target
图1 胆管癌细胞分泌外泌体示意图
图2 胆管癌致癌miRNA作用示意图
图3 胆管癌抑癌miRNA作用示意图
[1]
Shin DW, Moon SH, Kim JH. Diagnosis of cholangiocarcinoma[J]. Diagnostics, 2023, 13(2): 233.DOI: 10.3390/diagnostics13020233.
[2]
Ilyas SI, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma: evolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol, 2018, 15(2): 95-111.DOI: 10.1038/nrclinonc.2017.157.
[3]
Mavros MN, Economopoulos KP, Alexiou VG, et al. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis[J]. JAMA Surg, 2014, 149(6): 565.DOI: 10.1001/jamasurg.2013.5137.
[4]
Capuozzo M, Santorsola M, Landi L, et al. Evolution of treatment in advanced cholangiocarcinoma: old and new towards precision oncology[J]. Int J Mol Sci, 2022, 23(23): 15124.DOI: 10.3390/ijms232315124.
[5]
Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends[J]. J Cell Biol, 2013, 200(4): 373-383.DOI: 10.1083/jcb.201211138.
[6]
Dilsiz N. Role of exosomes and exosomal microRNAs in cancer[J]. Future Sci OA, 2020, 6(4): FSO465.DOI: 10.2144/fsoa-2019-0116.
[7]
Dutta S, Reamtong O, Panvongsa W, et al. Proteomics profiling of cholangiocarcinoma exosomes: a potential role of oncogenic protein transferring in cancer progression[J]. Biochim Biophys Acta, 2015, 1852(9): 1989-1999.DOI: 10.1016/j.bbadis.2015.06.024.
[8]
Janpipatkul K, Suksen K, Borwornpinyo S, et al. Downregulation of LAT1 expression suppresses cholangiocarcinoma cell invasion and migration[J]. Cell Signal, 2014, 26(8): 1668-1679.DOI: 10.1016/j.cellsig.2014.04.002.
[9]
Lin H, Huang JF, Qiu JR, et al. Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer[J]. Exp Mol Pathol, 2013, 94(1): 73-78.DOI: 10.1016/j.yexmp.2012.08.004.
[10]
Scheffer GL, Schroeijers AB, Izquierdo MA, et al. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer[J]. Curr Opin Oncol, 2000, 12(6): 550-556.DOI: 10.1097/00001622-200011000-00007.
[11]
Liu Z, Hu C, Zheng L, et al. BMI1 promotes cholangiocarcinoma progression and correlates with antitumor immunity in an exosome-dependent manner[J]. Cell Mol Life Sci, 2022, 79(9): 469.DOI: 10.1007/s00018-022-04500-1.
[12]
Liu Z, Zhou K, Zeng J, et al. Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma[J]. Oncol Rep, 2022, 48(3): 155.DOI: 10.3892/or.2022.8367.
[13]
Park YS, Yoo CW, Lee SC, et al. Lipid profiles for intrahepatic cholangiocarcinoma identified using matrix-assisted laser desorption/ionization mass spectrometry[J]. Clin Chim Acta, 2011, 412(21-22): 1978-1982.DOI: 10.1016/j.cca.2011.07.008.
[14]
Yu HJ, Moon MH. Direct lipid analysis of exosomes in serum by online miniaturized asymmetrical flow field-flow fractionation and electrospray ionization-mass spectrometry: application to extrahepatic cholangiocarcinoma[J]. J Chromatogr A, 2025, 1746: 465778.DOI: 10.1016/j.chroma.2025.465778.
[15]
Wang LJ, He CC, Sui X, et al. miR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN[J]. Oncotarget, 2015, 6(8): 5932-5946.DOI: 10.18632/oncotarget.3465.
[16]
An F, Olaru A, Mezey E, et al. microRNA-224 induces G1/S checkpoint release in liver cancer[J]. J Clin Med, 2015, 4(9): 1713-1728.DOI: 10.3390/jcm4091713.
[17]
Han Y, Meng F, Venter J, et al. miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth[J]. J Hepatol, 2016, 64(6): 1295-1304.DOI: 10.1016/j.jhep.2016.02.024.
[18]
Li H, Zhou ZQ, Yang ZR, et al. microRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma[J]. Hepatology, 2017, 66(1): 136-151.DOI: 10.1002/hep.29116.
[19]
Goeppert B, Ernst C, Baer C, et al. Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma[J]. Epigenetics, 2016, 11(11): 780-790.DOI: 10.1080/15592294.2016.1227899.
[20]
Hu C, Huang F, Deng G, et al. miR-31 promotes oncogenesis in intrahepatic cholangiocarcinoma cells via the direct suppression of RASA1[J]. Exp Ther Med, 2013, 6(5): 1265-1270.DOI: 10.3892/etm.2013.1311.
[21]
Zhong XY, Yu JH, Zhang WG, et al. microRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression[J]. Gene, 2012, 493(1): 44-51.DOI: 10.1016/j.gene.2011.11.028.
[22]
Razumilava N, Bronk SF, Smoot RL, et al. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma[J]. Hepatology, 2012, 55(2): 465-475.DOI: 10.1002/hep.24698.
[23]
Wang J, Xie C, Pan S, et al. N-myc downstream-regulated gene 2 inhibits human cholangiocarcinoma progression and is regulated by leukemia inhibitory factor/MicroRNA-181c negative feedback pathway[J]. Hepatology, 2016, 64(5): 1606-1622.DOI: 10.1002/hep.28781.
[24]
Li J, Yao L, Li G, et al. miR-221 promotes epithelial-mesenchymal transition through targeting PTEN and forms a positive feedback loop with β-catenin/c-Jun signaling pathway in extrahepatic cholangiocarcinoma[J]. PLoS One, 2015, 10(10): e0141168.DOI: 10.1371/journal.pone.0141168.
[25]
Ehrlich L, Hall C, Venter J, et al. miR-24 inhibition increases menin expression and decreases cholangiocarcinoma proliferation[J]. Am J Pathol, 2017, 187(3): 570-580.DOI: 10.1016/j.ajpath.2016.10.021.
[26]
Kitdumrongthum S, Metheetrairut C, Charoensawan V, et al. Dysregulated microRNA expression profiles in cholangiocarcinoma cell-derived exosomes[J]. Life Sci, 2018, 210: 65-75.DOI: 10.1016/j.lfs.2018.08.058.
[27]
Olaru AV, Ghiaur G, Yamanaka S, et al. microRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint[J]. Hepatology, 2010, 54(6): 2089-2098.DOI: 10.1002/hep.24591.
[28]
Zhu H, Mi Y, Jiang X, et al. Hepatocyte nuclear factor 6 inhibits the growth and metastasis of cholangiocarcinoma cells by regulating miR-122[J]. J Cancer Res Clin Oncol, 2016, 142(5): 969-980.DOI: 10.1007/s00432-016-2121-8.
[29]
Mott JL, Kobayashi S, Bronk SF, et al. miR-29 regulates Mcl-1 protein expression and apoptosis[J]. Oncogene, 2007, 26(42): 6133-6140.DOI: 10.1038/sj.onc.1210436.
[30]
Palumbo T, Poultsides GA, Kouraklis G, et al. A functional microRNA library screen reveals miR-410 as a novel anti-apoptotic regulator of cholangiocarcinoma[J]. BMC Cancer, 2016, 16(1): 353.DOI: 10.1186/s12885-016-2384-0.
[31]
Zhu L, Huang F, Deng G, et al. microRNA-212 targets FOXA1 and suppresses the proliferation and invasion of intrahepatic cholangiocarcinoma cells[J]. Exp Ther Med, 2016, 12(6): 3790-3796.DOI: 10.3892/etm.2016.3824.
[32]
Xiong X, Sun D, Chai H, et al. miR-145 functions as a tumor suppressor targeting NUAK1 in human intrahepatic cholangiocarcinoma[J]. Biochem Biophys Res Commun, 2015, 465(2): 262-269.DOI: 10.1016/j.bbrc.2015.08.013.
[33]
Wu X, Xia M, Chen D, et al. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma[J]. Tumor Biol, 2016, 37(11): 15019-15029.DOI: 10.1007/s13277-016-5313-6.
[34]
Wang Q, Tang H, Yin S, et al. Downregulation of microRNA-138 enhances the proliferation, migration and invasion of cholangiocarcinoma cells through the upregulation of RhoC/p-ERK/MMP-2/MMP-9[J]. Oncol Rep, 2013, 29(5): 2046-2052.DOI: 10.3892/or.2013.2304.
[35]
Oishi N, Kumar MR, Roessler S, et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma[J]. Hepatology, 2012, 56(5): 1792-1803.DOI: 10.1002/hep.25890.
[36]
Iwaki J, Kikuchi K, Mizuguchi Y, et al. miR-376c down-regulation accelerates EGF-dependent migration by targeting GRB2 in the HuCCT1 human intrahepatic cholangiocarcinoma cell line[J]. PLoS One, 2013, 8(7): e69496.DOI: 10.1371/journal.pone.0069496.
[37]
Wang H, Li C, Jian Z, et al. TGF-β1 reduces miR-29a expression to promote tumorigenicity and metastasis of cholangiocarcinoma by targeting HDAC4[J]. PLoS One, 2015, 10(10): e0136703.DOI: 10.1371/journal.pone.0136703.
[38]
Li J, Tian F, Li D, et al. miR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression[J]. FEBS Lett, 2014, 588(18): 3491-3500.DOI: 10.1016/j.febslet.2014.08.008.
[39]
Zheng T, Hong X, Wang J, et al. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma[J]. Hepatology, 2014, 59(3): 935-946.DOI: 10.1002/hep.26705.
[40]
Meng F, Wehbe-Janek H, Henson R, et al. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes[J]. Oncogene, 2008, 27(3): 378-386.DOI: 10.1038/sj.onc.1210648.
[41]
Okamoto K, Miyoshi K, Murawaki Y. miR-29b, miR-205 and miR-221 enhance chemosensitivity to Gemcitabine in HuH28 human cholangiocarcinoma cells[J]. PLoS One, 2013, 8(10): e77623.DOI: 10.1371/journal.pone.0077623.
[42]
Li Q, Xia X, Ji J, et al. miR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1[J]. Oncotarget, 2017, 8(20): 33621-33630.DOI: 10.18632/oncotarget.16834.
[43]
Qin X, Lu M, Li G, et al. Downregulation of tumor-derived exosomal miR-34c induces cancer‐associated fibroblast activation to promote cholangiocarcinoma progress[J]. Cancer Cell Int, 2021, 21(1): 373.DOI: 10.1186/s12935-020-01726-6.
[44]
Shigehara K, Yokomuro S, Ishibashi O, et al. Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer[J]. PLoS One, 2011, 6(8): e23584.DOI: 10.1371/journal.pone.0023584.
[45]
Supradit K, Wongprasert K, Tangphatsornruang S, et al. microRNA profiling of exosomes derived from plasma and their potential as biomarkers for Opisthorchis viverrini-associated cholangiocarcinoma[J]. Acta Trop, 2024, 258: 107362.DOI: 10.1016/j.actatropica.2024.107362.
[46]
Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review[J]. Cancer Metastasis Rev, 2013, 32(3): 623-642.DOI: 10.1007/s10555-013-9441-9.
[47]
Statello L, Guo CJ, Chen LL, et al. Author Correction: gene regulation by long non-coding RNAs and its biological functions[J]. Nat Rev Mol Cell Biol, 2021, 22(2): 159.DOI: 10.1038/s41580-021-00330-4.
[48]
Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer[J]. Genom Proteom Bioinform, 2016, 14(1): 42-54.DOI: 10.1016/j.gpb.2015.09.006.
[49]
Ge X, Wang Y, Nie J, et al. The diagnostic/prognostic potential and molecular functions of long non-coding RNAs in the exosomes derived from the bile of human cholangiocarcinoma[J]. Oncotarget, 2017, 8(41): 69995-70005.DOI: 10.18632/oncotarget.19547.
[50]
Ni Q, Zhang H, Shi X, et al. Exosomal lncRNA HCG18 contributes to cholangiocarcinoma growth and metastasis through mediating miR-424-5p/SOX9 axis through PI3K/AKT pathway[J]. Cancer Gene Ther, 2023, 30(4): 582-595.DOI: 10.1038/s41417-022-00500-2.
[51]
Zhang W, Yan Y, Peng J, et al. Decoding roles of exosomal lncRNAs in tumor-immune regulation and therapeutic potential[J]. Cancers, 2023, 15(1): 286.DOI: 10.3390/cancers15010286.
[52]
Wang Q, Sun Z, Guo J, et al. Tumor-derived exosomal LINC01812 induces M2 macrophage polarization to promote perineural invasion in cholangiocarcinoma[J]. Cancer Lett, 2025, 617: 217596.DOI: 10.1016/j.canlet.2025.217596.
[53]
Wang X, Wang G, Wu Z, et al. Exosomal circ-PTPN22 and circ-ADAMTS6 mark T cell exhaustion and neutrophil extracellular traps in Asian intrahepatic cholangiocarcinoma[J]. Mol Ther Nucleic Acids, 2023, 31: 151-163.DOI: 10.1016/j.omtn.2022.12.012.
[54]
Yang L, Wilusz JE, Chen LL. Biogenesis and regulatory roles of circular RNAs[J]. Annu Rev Cell Dev Biol, 2022, 38: 263-289.DOI: 10.1146/annurev-cellbio-120420-125117.
[55]
Wang S, Hu Y, Lv X, et al. Circ-0000284 arouses malignant phenotype of cholangiocarcinoma cells and regulates the biological functions of peripheral cells through cellular communication[J]. Clin Sci, 2019, 133(18): 1935-1953.DOI: 10.1042/cs20190589.
[56]
Xu Y, Yao Y, Liu Y, et al. Elevation of circular RNA circ_0005230 facilitates cell growth and metastasis via sponging miR-1238 and miR-1299 in cholangiocarcinoma[J]. Aging, 2019, 11(7): 1907-1917.DOI: 10.18632/aging.101872.
[57]
Xu Y, Leng K, Yao Y, et al. A circular RNA, cholangiocarcinoma-associated circular RNA 1, contributes to cholangiocarcinoma progression, induces angiogenesis, and disrupts vascular endothelial barriers[J]. Hepatology, 2021, 73(4): 1419-1435.DOI: 10.1002/hep.31493.
[58]
Lu Q, Fang T. Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma[J]. J Clin Lab Anal, 2020, 34(4): e23138.DOI: 10.1002/jcla.23138.
[59]
Tu J, Chen W, Zheng L, et al. Circular RNA Circ0021205 promotes cholangiocarcinoma progression through miR-204-5p/RAB22A axis[J]. Front Cell Dev Biol, 2021, 9: 653207.DOI: 10.3389/fcell.2021.653207.
[60]
Chen S, Chen Z, Li Z, et al. Tumor-associated macrophages promote cholangiocarcinoma progression via exosomal Circ_0020256[J]. Cell Death Dis, 2022, 13: 94.DOI: 10.1038/s41419-022-04534-0.
[61]
Yuan Z, Xiong B, Liu L, et al. Exosomal circ_0037104 derived from Hu-MSCs inhibits cholangiocarcinoma progression by sponging miR-620 and targeting AFAP1[J]. J Biochem Mol Toxicol, 2024, 38(2): e23656.DOI: 10.1002/jbt.23656.
[62]
Wen N, Peng D, Xiong X, et al. Cholangiocarcinoma combined with biliary obstruction: an exosomal circRNA signature for diagnosis and early recurrence monitoring[J]. Signal Transduct Target Ther, 2024, 9: 107.DOI: 10.1038/s41392-024-01814-3.
[63]
Ernst C, Odom DT, Kutter C. The emergence of piRNAs against transposon invasion to preserve mammalian genome integrity[J]. Nat Commun, 2017, 8: 1411.DOI: 10.1038/s41467-017-01049-7.
[64]
Gu X, Wang C, Deng H, et al. Exosomal PiRNA profiling revealed unique circulating PiRNA signatures of cholangiocarcinoma and gallbladder carcinoma[J]. Acta Biochim Biophys Sin, 2020, 52(5): 475-484.DOI: 10.1093/abbs/gmaa028.
[65]
Ahmadi Asouri S, Aghadavood E, Mirzaei H, et al. PIWI-interacting RNAs (PiRNAs) as emerging biomarkers and therapeutic targets in biliary tract cancers: a comprehensive review[J]. Heliyon, 2024, 10(13): e33767.DOI: 10.1016/j.heliyon.2024.e33767.
[66]
Mondal SK, Whiteside TL. Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression[J]. Melanoma Res, 2021, 31(5): 472-475.DOI: 10.1097/cmr.0000000000000762.
[67]
Yang R, Wang D, Han S, et al. miR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs[J]. Int J Biol Sci, 2022, 18(1): 43-64.DOI: 10.7150/ijbs.62602.
[68]
Aoki S, Inoue K, Klein S, et al. Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma[J]. Gut, 2022, 71(1): 185-193.DOI: 10.1136/gutjnl-2020-322493.
[69]
Jiang W, Shi X, Sun L, et al. Exosomal miR-30a-5p promoted intrahepatic cholangiocarcinoma progression by increasing angiogenesis and vascular permeability in PDCD10 dependent manner[J]. Int J Biol Sci, 2023, 19(14): 4571-4587.DOI: 10.7150/ijbs.83170.
[70]
Han JY, Ahn KS, Kim YH, et al. Circulating microRNAs as biomarkers in bile-derived exosomes of cholangiocarcinoma[J]. Ann Surg Treat Res, 2021, 101(3): 140.DOI: 10.4174/astr.2021.101.3.140.
[71]
Pan Y, Shao S, Sun H, et al. Bile-derived exosome noncoding RNAs as potential diagnostic and prognostic biomarkers for cholangiocarcinoma[J]. Front Oncol, 2022, 12: 985089.DOI: 10.3389/fonc.2022.985089.
[72]
Wang J, Jiang W, Liu S, et al. Exosome-derived miR-182-5p promoted cholangiocarcinoma progression and vasculogenesis by regulating ADK/SEMA5a/PI3K pathway[J]. Liver Int, 2024, 44(2): 370-388.DOI: 10.1111/liv.15773.
[73]
Uchihata Y, Arihiro K, Kaneko Y, et al. Analysis of microRNA in bile cytologic samples is useful for detection and diagnosis of extrahepatic cholangiocarcinoma[J]. Am J Clin Pathol, 2022, 158(1): 122-131.DOI: 10.1093/ajcp/aqac015.
[74]
Shu L, Li X, Liu Z, et al. Bile exosomal miR-182/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation[J]. Hepatology, 2024, 79(2): 307-322.DOI: 10.1097/hep.0000000000000437.
[75]
Zhong X, Zhang H, Zhu Y, et al. Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy[J]. Mol Cancer, 2020, 19(1): 15.DOI: 10.1186/s12943-020-1141-9.
[76]
Thakur A, Parra DC, Motallebnejad P, et al. Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics[J]. Bioact Mater, 2022, 10: 281-294.DOI: 10.1016/j.bioactmat.2021.08.029.
[77]
Zhou X, Kong X, Lu J, et al. Circulating tumor cell-derived exosome-transmitted long non-coding RNA TTN-AS1 can promote the proliferation and migration of cholangiocarcinoma cells[J]. J Nanobiotechnol, 2024, 22(1): 191.DOI: 10.1186/s12951-024-02459-8.
[78]
Weeraphan C, Phongdara A, Chaiyawat P, et al. Phosphoproteome profiling of isogenic cancer cell-derived exosome reveals HSP90 as a potential marker for human cholangiocarcinoma[J]. Proteomics, 2019, 19(12): 1800159.DOI: 10.1002/pmic.201800159.
[79]
Ikeda C, Haga H, Makino N, et al. Utility of Claudin-3 in extracellular vesicles from human bile as biomarkers of cholangiocarcinoma[J]. Sci Rep, 2021, 11: 1195.DOI: 10.1038/s41598-021-81023-y.
[80]
Arbelaiz A, Azkargorta M, Krawczyk M, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma[J]. Hepatology, 2017, 66(4): 1125-1143.DOI: 10.1002/hep.29291.
[81]
Shen L, Chen G, Xia Q, et al. Exosomal miR-200 family as serum biomarkers for early detection and prognostic prediction of cholangiocarcinoma[J]. Int J Clin Exp Pathol, 2019, 12(10): 3870-3876.
[82]
Ota Y, Takahashi K, Otake S, et al. Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition[J]. Oncotarget, 2018, 9(23): 16400-16417.DOI: 10.18632/oncotarget.24711.
[83]
Hu C, Zhang Y, Zhang M, et al. Exosomal cripto-1 serves as a potential biomarker for perihilar cholangiocarcinoma[J]. Front Oncol, 2021, 11: 730615.DOI: 10.3389/fonc.2021.730615.
[84]
Wang S, Yin J, Li T, et al. Upregulated circulating miR-150 is associated with the risk of intrahepatic cholangiocarcinoma[J]. Oncol Rep, 2015, 33(2): 819-825.DOI: 10.3892/or.2014.3641.
[85]
Chen M, Li Y, Ma N, et al. Mesenchymal stem cell-derived exosomes loaded with 5-Fu against cholangiocarcinoma in vitro[J]. Mol Med Rep, 2022, 25(6): 213.DOI: 10.3892/mmr.2022.12729.
[86]
Gao Y, Zhang H, Zhou N, et al. Methotrexate-loaded tumour-cell-derived microvesicles can relieve biliary obstruction in patients with extrahepatic cholangiocarcinoma[J]. Nat Biomed Eng, 2020, 4(7): 743-753.DOI: 10.1038/s41551-020-0583-0.
[87]
Luo C, Xin H, Zhou Z, et al. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression[J]. Hepatology, 2022, 76(4): 982-999.DOI: 10.1002/hep.32387.
[88]
Song F, Xu D, Che J, et al. Chitosan hydrogel incorporated with bone marrow mesenchymal stem cell-derived exosomal TIMP2 to inhibit angiogenesis in cholangiocarcinoma[J]. Tissue Cell, 2025, 93: 102694.DOI: 10.1016/j.tice.2024.102694.
[1] 赵彬, 周俊鹏, 王芳, 张伟, 杨晨. 负载人脂肪间充质干细胞外泌体的人脱细胞羊膜对小鼠全层皮肤缺损创面愈合的影响[J/OL]. 中华损伤与修复杂志(电子版), 2026, 21(03): 208-215.
[2] 陈劲松, 雷雪涛, 董毅. 免疫检查点抑制剂在胃癌治疗中的应用现状[J/OL]. 中华普通外科学文献(电子版), 2026, 20(03): 200-206.
[3] 邓励旺, 黄予希, 刘施沂, 李彬. 肝内胆管癌中三级淋巴结构及其他病理特征对预后的影响[J/OL]. 中华普通外科学文献(电子版), 2026, 20(02): 91-97.
[4] 李晶晶, 闫伟娜, 贾波, 刘灿, 徐竟益. 肝门部胆管癌胆道穿刺引流后胆汁回输的临床价值与研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(04): 390-393.
[5] 李坚, 张伟, 曾少杰, 母德安. 经皮穿刺消融治疗与腹腔镜肝脏切除术治疗早期肝内胆管癌的临床效果对比研究[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(02): 187-190.
[6] 李俊杰, 董培, 姚成, 刘泽, 李勇. 前列腺癌免疫治疗的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(02): 209-215.
[7] 姜海珍, 江煜焓, 张丹, 陈晨晨. 骨髓间充质干细胞外泌体调控TLR4/NF-κB信号通路缓解小鼠子宫内膜异位症研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(03): 140-149.
[8] 白宗科, 李忠. 干细胞治疗老年相关疾病的临床研究进展（2023-2025）[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(03): 176-184.
[9] 方睿, 于胜强. 干细胞外泌体介导的肾脏保护：阻止纤维化进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(02): 94-101.
[10] 马煜博, 李起, 耿智敏. 胆道恶性肿瘤预后预测模型：现状、挑战与未来展望[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(05): 702-710.
[11] 王琛, 徐芳, 周芳, 刘锦, 盛芳. 脂肪性肝病对晚期ICC系统治疗疗效及生存预后的影响[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(02): 226-233.
[12] 王逸敏, 刘爱连. 免疫微环境调控直肠癌淋巴结转移的机制及其相关影像学研究进展[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(04): 349-355.
[13] 林佳仪, 黄颖. Treg细胞在结直肠癌中的作用机制及靶向治疗研究进展[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(04): 356-360.
[14] 张逸辰, 冯雨舟, 鲍传庆. PROTAC在结直肠癌肿瘤微环境治疗中的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(02): 175-180.
[15] 王肖健, 李毫, 顾俊鹏, 阿斯哈尔·哈斯木, 刘建华, 任伟新. 125I粒子条联合胆道支架治疗不可切除Ⅲ和Ⅳ型肝门部胆管癌的对比研究[J/OL]. 中华介入放射学电子杂志, 2026, 14(03): 257-264.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？